Deferoxamine Has No Oral Dosing Regimen
Deferoxamine is not absorbed effectively by the gastrointestinal tract and must be administered parenterally—there is no oral dosing regimen for this medication. 1
Why Deferoxamine Cannot Be Given Orally
Deferoxamine is a hexadentate iron chelator with poor oral bioavailability due to ineffective gastrointestinal absorption. The drug's pharmacokinetic properties require parenteral administration (subcutaneous or intravenous) to achieve therapeutic iron chelation 1, 2.
Approved Routes of Administration
For Chronic Iron Overload
Subcutaneous infusion is the standard route:
- Dose range: 20-60 mg/kg/day 2
- Administration: 8-12 hour infusion via portable pump, 5-7 days per week 1, 2
- Typical dosing by ferritin level:
- Ferritin <2,000 ng/mL: ~25 mg/kg/day
- Ferritin 2,000-3,000 ng/mL: ~35 mg/kg/day
- Higher ferritin: up to 55 mg/kg/day 2
Intravenous administration for patients with IV access or heart failure:
- Adults: 40-50 mg/kg/day over 8-12 hours at ≤15 mg/kg/hour, maximum 60 mg/kg/day 2
- Pediatric: 20-40 mg/kg/day over 8-12 hours, maximum 40 mg/kg/day 2
For Acute Iron Intoxication
- Intramuscular: 1,000 mg initially, then 500 mg every 4-12 hours (maximum 6,000 mg/24 hours) 2
- Intravenous: For cardiovascular collapse only, 1,000 mg at ≤15 mg/kg/hour initially 2
Alternative Oral Iron Chelators
If oral administration is required, consider these FDA-approved alternatives:
Critical Safety Considerations
Do not exceed 50 mg/kg/day average dose except when intensive chelation is needed in patients who have completed growth, as toxicity risk increases significantly when ferritin falls below 1,000 ng/mL 2. Regular monitoring of ophthalmologic and audiological function, along with growth parameters in children, is mandatory due to risks of sensorineural deafness, visual disturbances, and skeletal abnormalities 1.